Publicaciones en las que colabora con Vicente Estrada Pérez (24)

2023

  1. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry

    Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

  3. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

    Internal and Emergency Medicine, Vol. 16, Núm. 4, pp. 957-966

  4. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

  5. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score

    Frontiers in Medicine, Vol. 8

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  3. Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

    Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154

2019

  1. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    The Lancet, Vol. 393, Núm. 10167, pp. 143-155

  2. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505

  3. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379

  4. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438

2016

  1. Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 517-523

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 516.e1-516.e18

  4. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy

    JAMA - Journal of the American Medical Association, Vol. 316, Núm. 2, pp. 171-181

2012

  1. Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study

    Current HIV Research, Vol. 10, Núm. 8, pp. 673-678